The article presents a novel gas-chemical approach for Ac/Bi generators, which provides effective separation of Bi from parent Ac. The main problem with the generators of high activity is the radiation stability of sorbents, which is not substantial in this gas-chemical method of separation, where only radiationally stable inorganic materials are used. The approach includes heating at high temperature (about 900-1000 °C) Ac sample deposited on a backing material (Nb, quartz glass, stainless steel) in hydrogen-containing inert gas flow. Actinium is non-volatile in these conditions, while Bi sublimes and is deposited on a catcher-foil along a temperature gradient. Niobium was found to be the best of the used material for both the starting backing and catcher-foil. The effective activation energy of carrier-free amount of Bi-sublimation from Nb-backing as 102 ± 9 kJ/mol has been calculated, and standard enthalpy of desorption of Bi on Nb from thermochromatographic data has been evaluated as 269 ± 13 kJ/mol Bi may be recovered for the consequent preparation of radiopharmaceuticals by washing from the catcher-foil surface. The gas-chemical method has been demonstrated to be a promising approach for Ac/Bi generators for its application in targeted alpha therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2024.111581DOI Listing

Publication Analysis

Top Keywords

approach ac/bi
12
gas-chemical approach
8
ac/bi generators
8
gas-chemical method
8
gas-chemical
4
ac/bi radionuclide
4
radionuclide generator
4
generator medical
4
medical application
4
application article
4

Similar Publications

Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.

Australas Radiol

November 1999

Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Kogarah, New South Wales, Australia.

There can be little doubt that one of the most important problems in the management of cancer is control of metastatic disease. This objective must be achieved ideally with a systemic therapeutic modality that targets cancer cells and gives minimal collateral damage to critical normal cells. The efficacy of targeted cancer therapy relies on the ability of a toxin to be located in the target cancer cell.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!